Charles River Labs Q1 Earnings Beat Estimates but Lowers FY2026 Forecast
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 08 2026
0mins
Source: Newsfilter
- Earnings Beat: Charles River Laboratories exceeded Q1 earnings estimates, indicating strong performance in the biopharmaceutical services sector, although specific figures were not disclosed, this result boosts investor confidence.
- FY2026 Forecast Cut: The company lowered its FY2026 forecast, reflecting uncertainties in the future market environment, which may impact investor confidence in long-term growth.
- Analysts Maintain Positive Outlook: Despite the forecast cut, analysts remain optimistic about Charles River Labs, raising price targets, indicating strong market confidence in the company's future development.
- Positive Market Reaction: Investors reacted positively to the analysts' optimistic outlook, which may drive stock prices up in the short term, further solidifying the company's position in the biopharmaceutical services market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRL
Wall Street analysts forecast CRL stock price to fall
12 Analyst Rating
9 Buy
3 Hold
0 Sell
Strong Buy
Current: 231.430
Low
185.00
Averages
226.70
High
265.00
Current: 231.430
Low
185.00
Averages
226.70
High
265.00
About CRL
Charles River Laboratories International, Inc. is a drug development company. It provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. Its Research Models and Services segment includes three businesses that provide foundational tools that enable its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Market Capitalization Comparison of Bio-Techne and Charles River Laboratories
- Market Cap Comparison: Bio-Techne Corp (Ticker: TECH) has a market capitalization of $11.06 billion, compared to Charles River Laboratories International Inc. (Ticker: CRL) at $10.92 billion, highlighting their relative size differences in the market.
- Investor Misconceptions: Many novice investors mistakenly compare companies solely based on stock price, overlooking market capitalization as a crucial metric, which can lead to misunderstandings about a company's true value and underscores the importance of market cap in investment decisions.
- Market Positioning Impact: Market capitalization not only affects a company's ranking among peers but also determines which mutual funds and ETFs may invest in these stocks, particularly as large funds tend to favor companies with market caps exceeding $10 billion.
- Stock Performance: At Wednesday's closing bell, TECH's stock rose approximately 0.5%, while CRL's stock remained flat, reflecting differing investor sentiments and expectations towards the two companies.
See More
Analysis of the Importance of Market Capitalization
- Market Capitalization Comparison: Charles River Laboratories International Inc. (CRL) has a market cap of $10.92 billion compared to Norwegian Cruise Line Holdings Ltd (NCLH) at $9.69 billion, indicating CRL's relative strength in attracting larger investors.
- Investor Misconceptions: Many novice investors mistakenly believe that a higher stock price equates to greater company value, but market capitalization provides a more accurate comparison, enabling better-informed investment decisions.
- Size Impact: Market capitalization determines a company's size tier among peers, directly influencing which mutual funds and ETFs are willing to hold the stock, particularly as large funds prefer companies valued over $10 billion.
- Index Influence: For instance, the S&P MidCap index focuses on smaller companies by excluding the largest 100, highlighting the significance of market capitalization in investment strategies and company performance, especially in favorable market conditions.
See More
Nike Shares Plummet, Underperforming in Dow Industrials
- Nike Stock Decline: Nike shares have fallen nearly 20% over the past three months and are down 48% from the August 2025 high, making it the worst performer in the Dow Industrials, only better than Chevron, indicating significant weakness in its market position.
- Year-to-Date Performance: Year-to-date, Nike's stock is down about 35%, and no other Dow constituent has performed worse in the past 12 months, highlighting the challenges it faces in the highly competitive sports apparel market.
- Constellation Brands Struggles: Constellation Brands, the maker of Corona and Modelo beers, has seen its stock drop nearly 8% in the last three months and is down 21% from its July 2025 high, reflecting pressure in its market segment.
- Healthcare Sector Strength: The healthcare sector has risen nearly 8% in the past month, with Moderna's stock surging 47%, indicating a strong recovery in the sector and investor confidence in its growth potential.
See More
Investment Comparison: Bio-Rad vs. Charles River Laboratories
- Bio-Rad Financial Performance: In FY 2025, Bio-Rad achieved nearly $2.6 billion in revenue, reflecting a year-over-year growth of approximately 0.6%, with net income improving to $759.9 million from a prior year loss of $1.8 billion, indicating a robust recovery in life sciences and clinical diagnostics.
- Charles River Market Positioning: Charles River's revenue slightly declined to over $4.0 billion in FY 2025, with a net loss of approximately $144.3 million, highlighting challenges in drug discovery; however, its diverse client base mitigates reliance on any single customer, enhancing business resilience.
- Competitive Risk Analysis: Bio-Rad faces significant competition from larger peers like Thermo Fisher and Danaher, with about 60% of its net sales coming from international operations, exposing it to currency fluctuations and complex foreign regulations that could impact future performance.
- Future Outlook and Strategy: Bio-Rad aims to enhance cash flow and utilize share buybacks to improve per-share ratios, despite a projected slight revenue decline to $2.57 billion in FY 2026, while Charles River expects to return to profitability with a projected net income of $285 million by focusing on high-margin businesses and achieving $100 million in cost savings.
See More
Investment Choice Between Bio-Rad and Charles River Laboratories
- Financial Performance Comparison: Bio-Rad's FY 2025 revenue reached nearly $2.6 billion, reflecting a year-over-year growth of approximately 0.6%, with a net income of $759.9 million, indicating a significant recovery from a prior year net loss of $1.8 billion, showcasing its improving profitability.
- Market Competition Analysis: Bio-Rad faces significant competition in the diagnostics market from larger peers like Thermo Fisher and Danaher, with approximately 60% of its net sales coming from international operations, exposing it to currency fluctuations and complex foreign regulations that could impact future growth.
- Charles River's Business Restructuring: Charles River's FY 2025 revenue was just over $4.0 billion, a slight decline of about 1%, but net income is projected to rebound to $285 million in 2026 as management focuses on higher-margin efforts and identifies $100 million in cost savings.
- Investment Outlook Assessment: While Bio-Rad currently exhibits stronger profitability, Charles River appears cheaper and is further along in its business restructuring, making it a more attractive investment choice for 2026.
See More
Mixed Performance in US Stock Indices, Chipmakers Lead Gains
- Strong Economic Data: US May retail sales rose 0.9% month-over-month, exceeding expectations of 0.6%, indicating resilient consumer demand that could positively impact future spending and economic recovery.
- Housing Market Recovery: Pending home sales in May increased by 3.8% month-over-month, significantly surpassing the expected 0.9%, marking the largest gain in 20 months, suggesting a rebound in the real estate market that may stimulate growth in related sectors.
- Oil Price Volatility: The agreement between the US and Iran to reopen the Strait of Hormuz has driven crude oil prices down to a 3.5-month low, increasing risk-on sentiment in the market, which may lead investors to reassess the risks and returns of energy-related assets.
- FOMC Meeting Focus: The market anticipates that the Federal Reserve will keep interest rates unchanged, but the press conference by new Chair Kevin Warsh will be pivotal, as investors closely watch his outlook on inflation to guide future investment decisions.
See More
Market Capitalization Comparison of Bio-Techne and Charles River Laboratories
- Market Cap Comparison: Bio-Techne Corp (Ticker: TECH) has a market capitalization of $11.06 billion, compared to Charles River Laboratories International Inc. (Ticker: CRL) at $10.92 billion, highlighting their relative size differences in the market.
- Investor Misconceptions: Many novice investors mistakenly compare companies solely based on stock price, overlooking market capitalization as a crucial metric, which can lead to misunderstandings about a company's true value and underscores the importance of market cap in investment decisions.
- Market Positioning Impact: Market capitalization not only affects a company's ranking among peers but also determines which mutual funds and ETFs may invest in these stocks, particularly as large funds tend to favor companies with market caps exceeding $10 billion.
- Stock Performance: At Wednesday's closing bell, TECH's stock rose approximately 0.5%, while CRL's stock remained flat, reflecting differing investor sentiments and expectations towards the two companies.
See More
Analysis of the Importance of Market Capitalization
- Market Capitalization Comparison: Charles River Laboratories International Inc. (CRL) has a market cap of $10.92 billion compared to Norwegian Cruise Line Holdings Ltd (NCLH) at $9.69 billion, indicating CRL's relative strength in attracting larger investors.
- Investor Misconceptions: Many novice investors mistakenly believe that a higher stock price equates to greater company value, but market capitalization provides a more accurate comparison, enabling better-informed investment decisions.
- Size Impact: Market capitalization determines a company's size tier among peers, directly influencing which mutual funds and ETFs are willing to hold the stock, particularly as large funds prefer companies valued over $10 billion.
- Index Influence: For instance, the S&P MidCap index focuses on smaller companies by excluding the largest 100, highlighting the significance of market capitalization in investment strategies and company performance, especially in favorable market conditions.
See More
Nike Shares Plummet, Underperforming in Dow Industrials
- Nike Stock Decline: Nike shares have fallen nearly 20% over the past three months and are down 48% from the August 2025 high, making it the worst performer in the Dow Industrials, only better than Chevron, indicating significant weakness in its market position.
- Year-to-Date Performance: Year-to-date, Nike's stock is down about 35%, and no other Dow constituent has performed worse in the past 12 months, highlighting the challenges it faces in the highly competitive sports apparel market.
- Constellation Brands Struggles: Constellation Brands, the maker of Corona and Modelo beers, has seen its stock drop nearly 8% in the last three months and is down 21% from its July 2025 high, reflecting pressure in its market segment.
- Healthcare Sector Strength: The healthcare sector has risen nearly 8% in the past month, with Moderna's stock surging 47%, indicating a strong recovery in the sector and investor confidence in its growth potential.
See More
Investment Comparison: Bio-Rad vs. Charles River Laboratories
- Bio-Rad Financial Performance: In FY 2025, Bio-Rad achieved nearly $2.6 billion in revenue, reflecting a year-over-year growth of approximately 0.6%, with net income improving to $759.9 million from a prior year loss of $1.8 billion, indicating a robust recovery in life sciences and clinical diagnostics.
- Charles River Market Positioning: Charles River's revenue slightly declined to over $4.0 billion in FY 2025, with a net loss of approximately $144.3 million, highlighting challenges in drug discovery; however, its diverse client base mitigates reliance on any single customer, enhancing business resilience.
- Competitive Risk Analysis: Bio-Rad faces significant competition from larger peers like Thermo Fisher and Danaher, with about 60% of its net sales coming from international operations, exposing it to currency fluctuations and complex foreign regulations that could impact future performance.
- Future Outlook and Strategy: Bio-Rad aims to enhance cash flow and utilize share buybacks to improve per-share ratios, despite a projected slight revenue decline to $2.57 billion in FY 2026, while Charles River expects to return to profitability with a projected net income of $285 million by focusing on high-margin businesses and achieving $100 million in cost savings.
See More
Investment Choice Between Bio-Rad and Charles River Laboratories
- Financial Performance Comparison: Bio-Rad's FY 2025 revenue reached nearly $2.6 billion, reflecting a year-over-year growth of approximately 0.6%, with a net income of $759.9 million, indicating a significant recovery from a prior year net loss of $1.8 billion, showcasing its improving profitability.
- Market Competition Analysis: Bio-Rad faces significant competition in the diagnostics market from larger peers like Thermo Fisher and Danaher, with approximately 60% of its net sales coming from international operations, exposing it to currency fluctuations and complex foreign regulations that could impact future growth.
- Charles River's Business Restructuring: Charles River's FY 2025 revenue was just over $4.0 billion, a slight decline of about 1%, but net income is projected to rebound to $285 million in 2026 as management focuses on higher-margin efforts and identifies $100 million in cost savings.
- Investment Outlook Assessment: While Bio-Rad currently exhibits stronger profitability, Charles River appears cheaper and is further along in its business restructuring, making it a more attractive investment choice for 2026.
See More
Mixed Performance in US Stock Indices, Chipmakers Lead Gains
- Strong Economic Data: US May retail sales rose 0.9% month-over-month, exceeding expectations of 0.6%, indicating resilient consumer demand that could positively impact future spending and economic recovery.
- Housing Market Recovery: Pending home sales in May increased by 3.8% month-over-month, significantly surpassing the expected 0.9%, marking the largest gain in 20 months, suggesting a rebound in the real estate market that may stimulate growth in related sectors.
- Oil Price Volatility: The agreement between the US and Iran to reopen the Strait of Hormuz has driven crude oil prices down to a 3.5-month low, increasing risk-on sentiment in the market, which may lead investors to reassess the risks and returns of energy-related assets.
- FOMC Meeting Focus: The market anticipates that the Federal Reserve will keep interest rates unchanged, but the press conference by new Chair Kevin Warsh will be pivotal, as investors closely watch his outlook on inflation to guide future investment decisions.
See More
